Provided are the use of a mutant Ovis spp. infectious pustular dermatitis virus (ORFV) and a pharmaceutical composition thereof in the treatment of cancer.

The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.

The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased munogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus vector and/or said cell, and a new use of said modified Parapoxvirus.

A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.

Provided are the use of a mutant Ovis spp. infectious pustular dermatitis virus (ORFV) and a pharmaceutical composition thereof in the treatment of cancer.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.